Neuland Laboratories Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mvir936prf8kineacrmkzdta.pdf

Key Takeaways


FY25 Performance: The Consolidation Year

Saharsh Davuluri: "Our business is uneven due to the inherent nature of the CDMO business as well as the specialty GDS business, which is focused on small volume products. As a result, evaluating Neuland's trajectory on a 3-year block basis is perhaps a more accurate measure than comparing quarter-to-quarter or even an annual basis."

Unit 3: The Immediate Growth Catalyst


CMS Pipeline: Second-Source Wins and Annual Commercializations

Saharsh Davuluri: "But definitely, what I can share is that it is a commercially approved drug. It's been out in the market for a few years now. The first source is non-Indian source and Neuland is getting added as a second source."

Peptides and Technical Differentiation

Saharsh Davuluri: "The quality of projects that are entering the system every year, the overall quality is only improving. And if I have to illustrate that, let's say, if we say, okay, how many INR100 crore opportunities are entering the system? Maybe 10 years ago, we would barely see INR100 crore CMS opportunity. I think today, we see a far higher number of INR100 crore opportunities."

Margins: Suboptimal FY25, Recovery Expected but Unquantified

Saharsh Davuluri: "I think whatever we have seen in FY24, I think we had also indicated that those are highly optimized kind of margins, right? I think very favorable exchange rates, raw material costs, product mix, etcetera. We had always said that that's more like a North Star of our margins. We don't expect that to be like a basis or a benchmark."

Growth Outlook: FY26 Recovery, No Quantitative Guidance

Saharsh Davuluri: "It actually points to the reality of our business, right? I think it shows that we're not really fully in control of our numbers. And it is for those several factors that I had also reiterated in the opening remarks today. A small shift in the product mix could have an impact. Exchange rate, raw material costs, a lot of things can contribute to this. I think these are some of the reasons why I think these kind of fluctuations happen. And I think that's the reason why we also hesitate to give any kind of guidance."

Guidance & Commitments

CommitmentSpecificsTimeline
Unit 3 commercial productionProduct validations ongoing; commercial supplies to beginFY26
Unit 3 revenue momentumGreater revenue momentum expected from commercialization of new production blockLatter half of FY26
Growth trajectory resumptionGrowth to resume on FY24 baseFY26
New CMS molecule commercializationOne additional molecule to be commercializedFY26
CMS annual commercializationOpportunities to commercialize molecules almost every year, with big molecules annuallyFY25–FY29
Peptide large-scale manufacturing₹300 crore investment in Unit 1 to create capabilities that currently do not exist at NeulandOn track (no date specified)
Margins directionMargins should go up from suboptimal FY25 levels; range not givenFY26

Key Metrics

MetricQ4 FY25
Total income₹335.8 cr, -14% YoY vs ₹390.4 cr
EBITDA₹58.2 cr, margin 17.3% vs ₹112.2 cr and 28.7% margin in Q4 FY24
Gross margin56.3% vs 58.8% in Q4 FY24
Profit after tax₹27.7 cr vs ₹67.6 cr in Q4 FY24
EPS₹21.6 per share
FY25 total income₹1,497.3 cr, -4.7% YoY vs ₹1,571.1 cr
FY25 EBITDA (excl. exceptional items of ₹7.6 cr)₹342.8 cr vs ₹474.5 cr in FY24
FY25 free cash flow₹111 cr
Net debtNegative ₹29 cr (net cash position)
Working capital107 days of sales at end of March
CMS revenues (FY25)~₹637 cr, largely driven by commercial molecules
Revenue from supplies to U.S.30% of total revenue
CMS pipeline projects97 total projects, up from 81 in FY22
CMS pre-registration molecules4, down from 6 QoQ
FY25 capital spends₹26.4 cr